Logo Logo

Publications by Kasper, S.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 5.

Journal article

Gastpar, M.; Müller, W. E.; Volz, H. P.; Möller, H. J.; Schläfke, S.; Dienel, A.; Kasper, S. (2017): Silexan does not cause withdrawal symptoms even when abruptly discontinued. In: International Journal of Psychiatry In Clinical Practice, Vol. 21, No. 3: pp. 177-180

Sturgess, R.; Palmer, D.; Trojan, J.; Hoffmeister, A.; Neu, B.; Kasper, S.; Dechêne, A.; Jürgensen, C.; Schirra, J.; Jakobs, R.; Høgset, A.; Finnesand, L. (2017): Phase I clinical study with photochemical internalisation, a novel technology for treatment of perihilar cholangiocarcinoma. In: Journal of Hepatology, Vol. 66, No. 1: S452-S452

Modest, D. P.; Kasper, S.; Stintzing, S.; Prasnikar, N.; Müller, L.; Caca, K.; Gökkurt, E.; Fischer von Weikersthal, L.; Kopp, H.-G.; Trarbach, T. (2016): Randomized phase II study of maintenance treatment with 5-FU/FA plus panitumumab vs 5-FU/FA alone after induction (mFOLFOX6 plus panitumumab) in patients with RASWT metastatic colorectal cancer. In: Annals of Oncology, Vol. 27

Rüssel, J.; Einem, J. von; Keilholz, U.; Dietz, A.; Grünewald, V; Maschmeyer, G.; Kasper, S.; Rupprecht, M.; Sasse, B.; Melillo, G.; Krauss, J. (2016): RAPTOR, the global phase II, III clinical development program of the PD-L1 inhibitor Durvalumab (MEDI4736) in 2nd-line recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) - A German update on the HAWK, EAGLE and CONDOR trials. In: Oncology Research and Treatment, Vol. 39: pp. 173-174

Danos, P.; Kasper, S.; Grunwald, F.; Klemm, E.; Krappel, C.; Broich, K.; Hoflich, G.; Overbeck, B.; Biersack, H. J.; Möller, Hans-Jürgen (1998): Pathological regional blood flow in opiate-dependent patients during withdrawal: A HMPAO-SPECT study. In: Neuropsychobiology, No. 4: pp. 194-199 [PDF, 326kB]

This list was generated on Sat Aug 8 01:44:32 2020 CEST.